trazodone and Obsessive-Compulsive Disorder

trazodone has been researched along with Obsessive-Compulsive Disorder in 22 studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.

Research

Studies (22)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Clinical Global Impression- Severity and Improvement (CGI)

"The entire study for the subject will last 5 weeks. Every two weeks and after the one week washout period the subject will complete the CGI. The change in scores from baseline to after 5 weeks will be assessed. The scale itself assesses overall disorder severity on a scale from 1 to 7 with 1 being not at all and 7 being among the most severe cases" (NCT03348930)
Timeframe: 2 weeks (start of study to washout period OR two weeks following washout period)

Hamilton Anxiety Rating Scale (HAM-A)

Every study visit, the subject will complete the HAM-A. The change in scores from baseline to after 5 weeks will be assessed. The scale itself assesses level of anxiety. Higher scores indicate higher levels of anxiety, with 0 being no symptoms of anxiety and 30 being severe anxiety. (NCT03348930)
Timeframe: 2 weeks (start of study to washout period OR two weeks following washout period)

Hamilton Depression Rating Scale (HAM-D)

The entire study for the subject will last 5 weeks. The HAM-D will be administered at every study visit. The change in scores from baseline to after the end of the 2-week active treatment period will be assessed and the change in scores from baseline to the end of the 2-week placebo period. The scale itself assesses level of depression. The minimum score is 0 and indicates no depressive symptoms, while the highest possible score is 50. Higher total scores indicate high levels of depression. Higher scores indicate a worse outcome. Higher total scored (14-50) indicate higher levels of depression, while a score between 0-7 is considered normal. (NCT03348930)
Timeframe: 2 weeks (start of study to washout period OR two weeks following washout period)

Sheehan Disability Scale (SDS)

The entire study for the subject will last 5 weeks. Every two weeks and after the one week washout period the subject will complete the SDS. The change in scores from baseline to after 5 weeks will be assessed. The scale itself assesses the level of disability from obsessive compulsive disorder (or target disorder). The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life. Work/school scores range from 0 to 10, Social life scores range from 0 to 10, Family life/home responsibilities scores range from 0 to 10). Total scores are calculated by adding the scores for work/school, social life, and family life. Total scores range from a minimum of 0 to a maximum of 30 (0 unimpaired, 30 highly impaired). (NCT03348930)
Timeframe: 2 weeks (start of study to washout period OR two weeks following washout period)

Yale Brown Obsessive Compulsive Scale (Y-BOCS)

The entire study for the subject will last 5 weeks. Every 2 weeks and after the one week washout period the subject will take the YBOCS. The change in scores from baseline to after 5 weeks will be assessed. The scale itself assesses severity of OCD symptoms. The YBOCS scale ranges from 0 to 40, with 0 being no symptoms and 40 being severe. (NCT03348930)
Timeframe: 2 weeks (start of study to washout period OR two weeks following washout period)

Reviews

1 review available for trazodone and Obsessive-Compulsive Disorder

Trials

2 trials available for trazodone and Obsessive-Compulsive Disorder

Other Studies

19 other studies available for trazodone and Obsessive-Compulsive Disorder